Cinclus Pharma

12.25

SEK

-3.6 %

Less than 1K followers

CINPHA

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview

Financials & Estimates

Ownership

-3.6%

-30.79%

-42.7%

-42.72%

-54.66%

-

-

-

-62.43%

Cinclus Pharma is a Swedish pharmaceutical company in the clinical phase. The company is active in the development of molecules for the treatment of acid-related diseases. The company's leading drug candidate linaprazan glurate is being developed for the treatment of severe gastroesophageal reflux disease (GERD). Cinclus Pharma was founded in 2014 and has its headquarters in Stockholm.

Market cap

580.55M SEK

Turnover

1.73M SEK

Revenue

4.58M

EBIT %

-3,703.93 %

P/E

-

Dividend yield-%

-

Financial calendar

19.5

2025

Interim report Q1'25

22.5

2025

General meeting '25

20.8

2025

Interim report Q2'25

ShowingAll content types

Press release2/20/2025, 1:59 PM

Redeye: Cinclus Pharma Q4 - Validation through market approval

Regulatory press release2/20/2025, 7:00 AM

Year-end report January – December 2024

Press release2/6/2025, 7:30 AM

Invitation to presentation of Cinclus Pharma’s fourth quarter report 2024

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Regulatory press release12/30/2024, 1:00 PM

Number of shares and votes in Cinclus Pharma

Regulatory press release12/4/2024, 2:40 PM

Linaprazan glurate receives marketing approval in China

Regulatory press release11/28/2024, 6:30 PM

Issue and repurchase of class C shares

Press release11/22/2024, 6:30 AM

Cinclus Pharma agrees on pediatric study plan with FDA

Press release11/14/2024, 2:27 PM

Redeye: Cinclus Pharma Q3 - Progress in preparations ahead of pivotal study

Regulatory press release11/14/2024, 7:00 AM

Interim Report January – September 2024

Regulatory press release11/8/2024, 8:00 AM

CINCLUS PHARMA’S NOMINATION COMMITTEE FOR THE 2025 ANNUAL GENERAL MEETING APPOINTED

Press release11/4/2024, 7:30 AM

Invitation to presentation of Cinclus Pharma’s third quarter report 2024

Press release10/29/2024, 6:30 AM

Cinclus Pharma agrees on Pediatric Investigation Plan (PIP) with EMA

Press release9/30/2024, 5:30 AM

Cinclus Pharma completes IMP manufacturing for phase III

Press release9/24/2024, 6:30 AM

Cinclus Pharma's data presented at UEG

Press release9/23/2024, 6:36 AM

Redeye: Redeye Initiates Coverage of Cinclus Pharma

Regulatory press release8/29/2024, 6:00 AM

CINCLUS PHARMA INTERIM REPORT APRIL-JUNE 2024

Press release8/26/2024, 6:00 AM

Invitation to presentation of Cinclus Pharma’s second quarter report 2024

Press release7/29/2024, 6:00 AM

Cinclus Pharma appoints PSI as CRO for its eGERD phase III program

Regulatory press release7/19/2024, 4:30 PM

Notice of stabilization, end of stabilization period and that the over-allotment option has not been exercised

Regulatory press release7/11/2024, 5:00 PM

Stabilization notice

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.